AIM: To assess the efficacy of combined transcatheter arterial chemoembolization (TACE) and percutaneous microwave coagulation therapy (PMCT) for small hepatocellular carcinoma (HCC). METHODS: Thirty-five patients with a total of 41 HCC nodules (<= 3 cm in diameter) were treated with TACE followed by computed tomograghy (CT)-guided percutaneous microwave coagulation therapy (PMCT) within 1-3 wk. RESULTS: By biopsies and enhanced CT scans, complete necrosis of the tumor and 3-5 mm of the surrounding non-cancerous area were observed in 34 foci. In seven foci, incomplete necrosis of the surrounding parenchyma was observed. Serum alpha-fetoprotein (AFP) levels returned to normal 10 d after treatment in 25 patients who originally had high serum AFP levels. The follow-up period was 6-31 mo, and all patients remained alive. One patient had a recurrence in the subsegments of the liver, and another patient had a recurrence near the original lesion. CONCLUSION: Combined therapy with TACE and PMCT is a safe and effective treatment without severe complications for small HCC.
AIM: To assess the efficacy of combined transcatheter arterial chemoembolization (TACE) and percutaneous microwave coagulation therapy (PMCT) for small hepatocellular carcinoma (HCC). METHODS: Thirty-five patients with a total of 41 HCC nodules (<= 3 cm in diameter) were treated with TACE followed by computed tomograghy (CT)-guided percutaneous microwave coagulation therapy (PMCT) within 1-3 wk. RESULTS: By biopsies and enhanced CT scans, complete necrosis of the tumor and 3-5 mm of the surrounding non-cancerous area were observed in 34 foci. In seven foci, incomplete necrosis of the surrounding parenchyma was observed. Serum alpha-fetoprotein (AFP) levels returned to normal 10 d after treatment in 25 patients who originally had high serum AFP levels. The follow-up period was 6-31 mo, and all patients remained alive. One patient had a recurrence in the subsegments of the liver, and another patient had a recurrence near the original lesion. CONCLUSION: Combined therapy with TACE and PMCT is a safe and effective treatment without severe complications for small HCC.
Authors: Nam C Yu; Steven S Raman; Young Jun Kim; Charles Lassman; Xinlian Chang; David S K Lu Journal: J Vasc Interv Radiol Date: 2008-05-27 Impact factor: 3.464
Authors: S Shiina; K Tagawa; T Unuma; H Fujino; Y Uta; Y Niwa; Y Hata; Y Komatsu; Y Shiratori; A Terano Journal: AJR Am J Roentgenol Date: 1990-12 Impact factor: 3.959
Authors: C Kuroda; M Sakurai; M Monden; T Marukawa; T Hosoki; K Tokunaga; K Wakasa; J Okamura; T Kozuka Journal: Cancer Date: 1991-01-01 Impact factor: 6.860
Authors: H Ishii; S Okada; H Nose; T Okusaka; M Yoshimori; T Takayama; T Kosuge; S Yamasaki; M Sakamoto; S Hirohashi Journal: Cancer Date: 1996-05-01 Impact factor: 6.860
Authors: S Shiina; K Tagawa; T Unuma; R Takanashi; K Yoshiura; Y Komatsu; Y Hata; Y Niwa; Y Shiratori; A Terano Journal: Cancer Date: 1991-10-01 Impact factor: 6.860
Authors: T Livraghi; L Bolondi; S Lazzaroni; G Marin; A Morabito; G L Rapaccini; A Salmi; G Torzilli Journal: Cancer Date: 1992-02-15 Impact factor: 6.860
Authors: T Kanai; S Hirohashi; M P Upton; M Noguchi; K Kishi; M Makuuchi; S Yamasaki; H Hasegawa; K Takayasu; N Moriyama Journal: Cancer Date: 1987-08-15 Impact factor: 6.860
Authors: Paul Revel-Mouroz; Philippe Otal; Marion Jaffro; Antoine Petermann; Olivier Meyrignac; Pierre Rabinel; Fatima-Zohra Mokrane Journal: Rep Pract Oncol Radiother Date: 2017-04-14
Authors: Michael Ginsburg; Sean P Zivin; Kristen Wroblewski; Taral Doshi; Raj J Vasnani; Thuong G Van Ha Journal: J Vasc Interv Radiol Date: 2014-12-18 Impact factor: 3.464
Authors: Thomas Josef Vogl; Jun Qian; Andreas Tran; Elsie Oppermann; Nagy N Naguib; Huedayi Korkusuz; Nour Eldin A Nour Eldin; Wolf Otto Bechstein Journal: Diagn Interv Radiol Date: 2017 Mar-Apr Impact factor: 2.630